Lung Cancer Master Protocol (Lung-MAP), a public-private partnership, established infrastructure for conducting a biomarker-driven master protocol in molecularly targeted therapies. We compared ...
Biomarker-driven master protocols represent a new paradigm in oncology clinical trials, but their complex designs and wide-ranging genomic results returned can be difficult to communicate to ...
Five biopharma companies will soon be testing their lung cancer compounds in a very different type of clinical trial. The Lung Cancer Master Protocol will test multiple novel drugs simultaneously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results